Clinical Trials Sponsored by Merck

Total 4981 results

Children's Mercy Hospital Kansas City
Merck Sharp & Dohme LLC

Completed

Montelukast in the Treatment of Duodenal Eosinophilia

Dyspepsia | Eosinophilic Gastroenteritis

United States
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)

Heart Failure, Congestive

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea (ECOS KOR)

Growth Disorders

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

Infertility

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control (GIANT)

Hypertension | Diabetes Mellitus, Type II

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])

Hypertension

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients. (ABBA)

Chronic Heart Failure

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Kft., Hungary

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary (ECOS HUN)

Growth Disorders

Hungary
Merck KGaA, Darmstadt, Germany
Merck A.E., Greece

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece (ECOS GRE)

Growth Disorders

Greece
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Colorectal Neoplasms

India
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Merck KGaA, Darmstadt, Germany
Merck A.E., Greece

Completed

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Multiple Sclerosis, Relapsing-Remitting

Greece
Merck KGaA, Darmstadt, Germany
Merck Ltd., Taiwan

Terminated

Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen

Infertility

Taiwan
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Terminated

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Infertility | Ovulation Induction

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Terminated

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Infertility | Ovulation Induction

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Fibromyalgia

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone (SGA)

Infant, Small for Gestational Age

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain (ECOS ESP)

Growth Disorders

Spain
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
Merck KGaA, Darmstadt, Germany
Merck Ltd., Thailand

Terminated

Glucophage XR® Observational Study

Diabetes Mellitus Type 2 | GI Side Effect

Thailand
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Withdrawn

Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets

Diabetes Mellitus Type 2
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands

Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (MESTRE-MS)

Multiple Sclerosis

Germany
Merck KGaA, Darmstadt, Germany
Merck S.A. Columbia

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia (ECOS COL)

Growth Disorders

Colombia
Merck KGaA, Darmstadt, Germany
Merck A.B., Sweden

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden (ECOS SWE)

Growth Disorders

Sweden
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Merck KGaA, Darmstadt, Germany
Merck Inc., Philippines

Completed

A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes

Hypertension

Philippines
Merck KGaA, Darmstadt, Germany
Merck Kft., Hungary

Completed

An Observational Study to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation in Assisted Reproductive Techniques (ESCORT)

Infertility

Hungary
Merck KGaA, Darmstadt, Germany
Merck d.o.o., Serbia

Completed

A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles (POINT)

Infertility

Serbia
Merck KGaA, Darmstadt, Germany
Merck Serono Norway

Completed

A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

Infertility

Norway
Merck KGaA, Darmstadt, Germany
Merck Ltd., Taiwan; Merck Pte. Ltd., Singapore; PT Merck Tbk., Indonesia, an...

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore) (ECOS TW ID SG)

Growth Disorders

Singapore, Taiwan, Indonesia
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

Multiple Sclerosis

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy (ECOS ITA)

Growth Disorders

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France (ECOS FRA)

Growth Disorders

France
Merck KGaA, Darmstadt, Germany
Merck Quimica Argentina S.A.I.C

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina (ECOS ARG)

Growth Disorders

Argentina
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (APEC)

Metastatic Colorectal Cancer

Singapore
Merck KGaA, Darmstadt, Germany
Merck N.V.-S.A., Belgium

Terminated

An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

Multifollicular Stimulation

Belgium
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany

Completed

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone) (LODOTRA)

Arthritis, Rheumatoid

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Assessment of Patient Use of a New Device: RebiSmart

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (ATTAC-PCO)

Polycystic Ovarian Syndrome

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study

Turner Syndrome | Idiopathic Growth Hormone Deficiency

Spain, France, Canada, United Kingdom, Czech Republic, Argentina, Germany, Italy, Sweden
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Terminated

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA) (SAIZEN in SGA)

Infant, Small for Gestational Age

Italy
Merck KGaA, Darmstadt, Germany
Merck Quimica Argentina S.A.I.C

Completed

Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing Remitting

Argentina
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. (SMART)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd.

Terminated

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Infertility

China

3

Subscribe